XML 105 R60.htm IDEA: XBRL DOCUMENT v3.24.1
Share-based compensation - Plans (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Jan. 01, 2024
Oct. 02, 2023
Sep. 29, 2023
Jan. 01, 2023
Sep. 18, 2020
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Expiration period           10 years  
Options, Granted           4,007,552  
Weighted average grant date fair value           $ 6.09 $ 2.65
Morphimmune Inc              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Exercise price   $ 1.29          
Dr. Clay Siegall | Morphimmune Inc              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Options, Granted           2,137,080  
Exercise price           $ 5.91  
Estimated grant date fair value   $ 14.2          
Weighted average grant date fair value   $ 6.65          
Dr. Clay Siegall | Morphimmune Inc | One-year anniversary              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Percentage of vesting   25.00%          
Dr. Clay Siegall | Morphimmune Inc | Over next 36 months              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period   36 months          
Percentage of vesting   75.00%          
Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period           4 years  
Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period           1 year  
2020 Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Threshold Percentage Of Total Number Of Common Stock Outstanding         4.00%    
Shares available for future issuance           3,320,601  
Increase in shares available for future issuance     2,955,280 485,153      
2020 Plan | Subsequent Event [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Increase in shares available for future issuance 1,730,071            
MorphImmune Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares available for future issuance   929,702          
Employee Stock Purchase Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares available for grant           473,733  
Increase in shares available for future issuance       121,288      
Authorized stock options           125,000  
Employee Stock Purchase Plan, Threshold Period For Which Common Stock Is Automatically Added To Arrive At Authorized Shares           10 years  
Percentage of outstanding capital stock           1.00%  
Number of common shares added in authorized           1,000,000  
Awards granted           0  
Employee Stock Purchase Plan | Subsequent Event [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Increase in shares available for future issuance 432,518